medigraphic.com
Boletín Médico del Hospital Infantil de México

2007, Number 1

<< Back Next >>

Bol Med Hosp Infant Mex 2007; 64 (1)

Visceral leishmaniasis treated with amphotericin B.

Hernández-Flores JJ, Morales-Aguirre JJ, Zamora-Chávez A

Language: Spanish
References: 35
Page: 43-48
PDF size: 212.76 Kb.


ABSTRACT

Introduction. Leishmaniasis is an endemic disease in more than 82 countries with a risk population of more than 350 million people worldwide. The World Health Organization estimates more than 12 million cases annually, with an annual incidence of more than 600 000 cases per year and 750 000 deaths.
Case report. We present a case of visceral leishmaniasis treated with amphotericin B in the Hospital Infantil de Mexico Federico Gomez. The patient was a 16 month old male from the state of Guerrero, who was admitted to the hospital with history of fever, pancitopenia, and hepatosplenomegally. After ruling out neoplastic and other infectious and non infectious causes of organ infiltration, a positive Leishmania serology was reported. The bone marrow aspirate was examined but was reported negative for amastygotes. Based on the serology, a presumptive diagnosis of visceral leishmaniasis was made. Treatment with amphotericin B, 1 mg/kg/day for 15 days resulted in significant clinical improvement.
Conclusion. Treatment of visceral leishmaniasis with amphotericin B instead of antimony is a good alternative, principally due to the high resistance reported in the treatment with antimonials.


REFERENCES

  1. Herwaldt B. Leishmaniasis. Lancet. 1999; 354: 1191-9.

  2. Córdova C, Albertos N, Andrade F, Canto S. Leishmaniasis: estudio preliminar en una localidad de la zona endémica del Estado de Tabasco. Salud Publica Mex. 1993; 35: 345-50.

  3. Life in the twenty-first century: a vision for all. World Health Report 1998. Geneva: World Health Organization; 1998. p. 45.

  4. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999; 12: 62-8.

  5. Desjeux P. Human leishmaniasis: Epidemiology and public health aspects. World Health Statist Q. 1992; 45: 267-75.

  6. Ashford RW. The leishmaniases as model zoonoses. Ann Trop Med Parasitol. 1997; 91: 693-701.

  7. Killick-Kendrick R. Phlebotomine vectors of the leishmaniasis: a review. Med Vet Entomol. 1990; 4: 1-24.

  8. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol. 1993; 5: 524-31.

  9. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997; 24: 684-703.

  10. Kalter DC. Laboratory test for the diagnosis and evaluation of leishmaniasis. Dermatol Clin. 1994; 12: 37-50.

  11. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg. 1983; 32: 475-9.

  12. Sundar S, Kumar K, Singh VP, Mahopatra TM. Diagnostic lag period in Kala-azar: test for early diagnostics hended. J Assoc Physicians India. 1991; 39: 651.

  13. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002; 9: 951-8.

  14. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992; 46: 296-306.

  15. Berman JD. Editorial response: U. S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999; 28: 49-51.

  16. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitates patients under wartime conditions and with limited resources. Ann Intern Med. 1996; 124: 664-72.

  17. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol. 1995; 34: 85-91.

  18. Kalter DC. Laboratory test for the diagnosis and evaluation of leishmaniasis. Dermatol Clin. 1994; 12: 37-50.

  19. Lightner LK, Chulay JD, Bryceson AD. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspiates. Am J Trop Med Hyg. 1983; 32: 296-9.

  20. Aikat BK, Sehgal S, Mehajan RC, Pathania AG, Bhattacharya PK, Sahaya S, et al. The role of counter immunoelectrophoresis as a diagnostic tool in kala-azar. Indian J Med Res. 1979; 70: 592-7.

  21. Haldar JP, Saha KC, Ghose AC. Serological profiles in Indian post kala-azar termal leishmaniasis. Trans R Soc Trop Med Hyg. 1981; 75: 514-7.

  22. Hockmeyer WT, Wellde BT, Sabwa CL, Smith DH, Rees PH, Kager PA. A complement fixation test for visceral leishmaniasis using homologous parasite antigen I. Ann Trop Med Parasitol. 1984; 78: 489-93.

  23. Sinha R, Sehgal S. Comparative evaluation of serological tests in Indian kala-azar. J Trop Med Hyg. 1994; 97: 333-40.

  24. Harith AE, Kolk AH, Kager PA, Leeuwenburg J, Faber FJ, Muigai R, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and seroepidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987; 81: 603-6.

  25. Badaro R, Reed SG, Carvalho EM, Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg. 1983; 32: 480-4.

  26. Boalaert M, Rijal S, Regmi S, Singh R, Karki B, Jacquet D, et al. A comparative study of the effectiveness of diagnostic test for visceral leishmaniasis. Am J Trop Med Hyg. 2004; 70: 72-7.

  27. Singla N, Sinh GS, Saundar S, Vinayak VK. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. Trans R Soc Trop Med Hyg. 1993; 87: 276-8.

  28. Gagnaire MH, Galambrun C, Stéphan JL. Hemophagocytic syndrome: A misleading complication of visceral leishmaniasis in children. A series of 12 cases. Pediatrics. 2000; 106: 101-6.

  29. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconato (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992; 46: 296-306.

  30. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992; 340: 1256-7.

  31. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999; 93: 319-23.

  32. Heimenz J, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996; 22: S133-44.

  33. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg. 2002; 66: 143-6.

  34. Thakur CP. A single dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents. 2001; 17: 67-70.

  35. Sundar S, Agrewal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ. 2001; 323: 419-22.




2020     |     www.medigraphic.com